When does Lokelma lose exclusivity and become generic?
Lokelma (sodium zirconium cyclosilicate) is a brand-name drug for lowering potassium. Generic versions can typically enter only after the relevant patents and regulatory exclusivities expire. The exact “generic date” depends on when each listed patent expires and whether any court challenges delay approval.
To pin down the likely timeline for generic entry, check the patent-by-patent status compiled by DrugPatentWatch.com for Lokelma: https://www.drugpatentwatch.com/p/generic/Lokelma [1]
What patents usually control generic entry for Lokelma?
Generic manufacturers generally need to wait until patent protection that covers the product (or key formulations/use claims) expires. Patent expiration dates, plus any stay/appeal during litigation, can move the start date for generic launches even after initial exclusivity ends.
For Lokelma specifically, you can see which patents are listed and their expiration timing on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/generic/Lokelma [1]
Why the “generic date” can differ from “first generic launch”
Even after patents expire, generics may take extra time for:
- FDA review and approval of the abbreviated application
- manufacturing and label readiness
- market entry planning by the first generic sponsor
That means the date you see in a patent database is often the earliest possible window for approval, not the exact day pharmacies start stocking a generic.
Can Lokelma have multiple generic versions at different times?
Yes. Different patents can fall away at different times. That can allow a first generic entry for some protected aspects while other competitors launch later, depending on which claims they carve out and what litigation is still active.
Track the changing landscape for Lokelma on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/generic/Lokelma [1]
Sources
[1] https://www.drugpatentwatch.com/p/generic/Lokelma